SCHEMBL4664203

SCHEMBL4664203

COc1ccc(NS(=O)(=O)c2ccc(-c3ccc(C)o3)c(F)c2)cc1NC(=O)C(C)(C)N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 6/20 0.44
ALDH1A1 P00352 8/20 0.43
MAPT P10636 6/20 0.43
KDM4E B2RXH2 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 8/20 0.41
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
HTT P42858 4/20 0.41
THRB P10828 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
KIT P10721 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664054 0.95 KDM4E (0.45) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL13245951 0.94 ALDH1A1 (0.46) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL2992279 0.90 GHSR (0.43) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL2979801 0.89 ALDH1A1 (0.50) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL13245970 0.86 ALDH1A1 (0.43) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL4664206 0.86 ALDH1A1 (0.43) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL13245995 0.86 GHSR (0.47) GHSRMAPTKDM4ELMNAHTT
SCHEMBL13245993 0.85 KDM4E (0.48) GHSRKDM4EPKM
SCHEMBL13245972 0.85 ALDH1A1 (0.45) GHSRALDH1A1MAPTKDM4ENPSR1
SCHEMBL2983496 0.84 ALDH1A1 (0.47) GHSRALDH1A1MAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007716-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-12-31 EP claimed
WO-2007118852-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-10-25 WO claimed
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS BLANEY EMMA LOUISE 2010-07-15 US disclosed
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS BLANEY EMMA LOUISE 2010-07-15 US disclosed
WO-2007118852-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GHSR, GHRHR, GIPR GHSR 1/4885ALDH1A1 2521/4885MAPT 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.